• Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;

• Age 18-65 years on the date of signing informed consent (inclusive);

• Body mass index (BMI) within the range of 19.0-40.0 kg/m2 (inclusive);

• Renal function, assessed by estimated glomerular filtration rate at screening (eGFR):

‣ Normal renal function: 90-129 mL/min (inclusive);

⁃ Mild impairment: 60-89 mL/min (inclusive);

⁃ Moderate impairment: 30-59 mL/min (inclusive);

⁃ Severe impairment: 15-29 mL/min (inclusive);

• Females of childbearing potential should have negative baseline blood pregnancy test, and must use highly effective contraception from signing the informed consent form to 2 months after the last dose of trial drug; Male subjects must agree to either remain abstinent or use highly effective contraceptive measures during the trial and 2 months after last dose of the trial drug, or have been surgically sterilized;

• Stable renal function, assessed by two eGFR during screening (apart at least 3 days);

• Diagnosed as stable, chronic renal disease for at least 3 months.